FIT IS AN EFFECTIVE RULE-IN TEST IN CRC SCREENING PROGRAMMES

The FIT is recommended in the European Guidelines for quality assurance in colorectal cancer screening and diagnosis.

The World Endoscopy Organization (WEO), Expert Working Group (EWG) ‘FIT for Screening’ focuses on implementing FIT screening around the world. The ‘EWG FIT for Screening’ group states that FIT is a better choice for population screening due to its superior performance characteristics compared to the guaiac Faecal Occult Blood test (gFOBt).

World Endoscopy Organization

'FIT for Screening'
To the website

‘Immunological tests are gaining ground’

Learn more about FIT CRC screening with Wolfert Spijker, CEO of the Organisation for Population Screening in the Netherlands.
Download Success Story

‘The benefits of using FIT for colorectal cancer screening’

Watch the webinar with Dr M. Spaander, Erasmus Medical Centre in Rotterdam, to learn about the experience of the Dutch colorectal cancer screening programme.
To our webinar

FIT HELPS TO RULE-OUT CRC IN PATIENTS WITH LOWER ABDOMINAL SYMPTOMS

NICE Diagnostic Guidance DG30 advises FIT to guide referral for colorectal cancer in primary care.

Symptoms associated with bowel disease include rectal bleeding and/or blood in the faeces, a change in bowel habit lasting three weeks or more, unexplained weight loss, anaemia or extreme tiredness for no obvious reason, a pain or lump in the abdomen and bloating. 

Although most people with these symptoms do not have a serious disease, they are very common problems in primary care and often physicians refer patients directly to secondary care for invasive investigation. With current colonoscopy resources in many countries being inadequate, an effective rule-out test prior to secondary care can be a solution.

The FIT that are used to detect bowel cancers in screening populations have shown to be equally effective in ruling out this cancer in symptomatic patients, thereby helping to avoid unnecessary colonoscopies. On the other hand, these tests can also detect CRC after  persons with symptoms have been seeking medical advice.

NICE DIAGNOSTIC GUIDANCE DG30  

News on NICE Diagnostic Guidance DG30

NICE Diagnostic Guidance DG30 recommends FIT to guide referral for colorectal cancer in primary care (published July 2017).  

FOBGold is recommended for adoption in primary care to guide referral for suspected colorectal cancer in patients without rectal bleeding who have unexplained symptoms but do not meet the criteria for a suspected cancer pathway referral outlined in the NICE guideline on suspected cancer (NG12).



Some helpful facts 
NICE DG30

  • … recommends using a cut-off of 10 µg Hb / g faeces with symptomatic populations.
  • … concluded that when using the cut-off of 10 µg Hb / g faeces, the FIT provides enough sensitivity to reliably rule out colorectal cancer in primary care.
  • … noted that FOBGold is compatible with a range of clinical chemistry analysers, which may be an advantage for laboratories.
  • … stated that FOBGold has potential to be a cost-effective option for triaging referrals to secondary care for people with symptoms but at low risk of colorectal cancer.

Who is entitled to an early-detection bowel cancer test?

The early-detection cancer directives differ slightly from country to county around Europe. Some countries organise CRC screening programmes on a national or regional level, and the eligible population is invited to participate formally. In other European countries, screening is still opportunistic and offered by accredited GPs and paid for by statutory health insurance schemes. 

There are three main tests in the majority of European countries, although this may differ slightly from country to country:

  • Faecal occult blood test (guaiac and immunochemical)
  • Sigmoidoscopy 
  • Colonoscopy

Please check with your local governmental authorities (guidelines and/or directives) regarding the status of preventive programmes in your region/country.

Advantages of an immunological stool test

Immunochemical tests for haemoglobin in stool (FIT) are used to detect small amounts of blood in stool. They are detected using antibodies that bind specifically to human haemoglobin.

Compared to the guaiac test, immunological tests have better specificity and sensitivity. Furthermore, they can be evaluated quantitatively in the laboratory.

ADVANTAGES OF THE SENTIFIT PIERCETUBE

  • The test is simple and the instructions are illustrated and easy to understand (video, PDF and package insert).
     
  • Grooves in the sampling stick and the integrated wiper filter ensure the correct amount of stool is collected.
     
  • The haemoglobin remains stable in the tube for 32 days at 2-8 degrees Celsius or for 14 days at 24-32 degrees Celsius.

How the FIT test works

Stool sampling with the SENTiFIT pierceTube is simple, hygienic and fast. Take a look at our one-minute video or download the PDF instructions.

FIT Infographic

Please click here to download an infographic simplified explanation of what is FIT and what it is used for.

Download PDF

Scientific STudies

TitleAuthorYear
 *FOBGold corresponds to SENTiFIT pierceTube 

Cancer is a challenge best faced together

Sysmex is proud to bring innovation for early recognition, individualising cancer therapy, and using less invasive diagnostics to improve prognoses and quality of life for colorectal cancer patients.